HDF/TERT1642024-01-02T07:20:33+00:00

Skin

HDF/TERT164

Evercyte ́s human dermal fibroblast cell line HDF/TERT164 can be grown without limitations while maintaining expression of cell type specific markers and functions. Therefore, these cells are frequently used as standardized in vitro model to study processes such as formation of the extracellular matrix, inflammation or wound healing. Moreover, the cells can be used to established relevant and standardizable 3D skin equivalents.

Print Friendly, PDF & Email

from

€ 1600,–

HDF/TERT164
Cat#: CHT-008-0164

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

Related Products

human foreskin fibroblasts fHDF/TERT166

Related Products

human lung fibroblasts LF/TERT309

Related Services

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about
our exosomes

extracellular vesicles from adipose-derived MSCs

news

Lecture on 3Rs

(replacement – reduction -refinement of animal experiments)

Related Products

Related Services

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email

from

€ 1300,–

HDF/TERT164
Cat#: CHT-008-0164

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

Title

Go to Top